Stem cell research conflict bill moves a step closer to ballot
By Knight Ridder,
Knight Ridder
| 05. 19. 2005
A measure to strengthen conflict-of-interest rules on Proposition 71-funded stem cell research cleared a second legislative hurdle Wednesday, even as critics warned it would scare off scientists.
The bill, SCA13, co-authored by Sens. Deborah Ortiz, D-Sacramento, and George Runner, R-Lancaster, passed the Senate committee on elections on a 5-0 vote. It is due to be considered next in the Senate Appropriations Committee on Monday.
The legislation would require the agency set up by Proposition 71, the measure voters approved in the fall to provide $3 billion toward stem cell research, to follow standards recently applied to the National Institutes of Health.
Those rules forbid employees from holding biotech or pharmaceutical stocks. SCA13 would extend the regulations to the California Institute for Regenerative Medicine, the agency overseeing the research, and its advisory groups.
To become law, the constitutional amendment must receive a two-thirds majority from both houses of the Legislature and be passed by the state's voters.
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
